Biotech Values

[dewophile]

It's really too bad bc we really need something for anticoagulation that can be combined safer w antiplatelet
plenty of people need both (Afib and TIA/stroke for example), and bleeding risks w current agents like eliquis + asa is high - it becomes a tightrope balancing stroke recurrence and bleeding
whether or not BMY should be taking a 5% hit on a project that was fairly high risk to begin with is another matter